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TGF-β, the most potent profibrogenic factor, acts by activating
SMAD (mothers against decapentaplegic) transcription factors,
which bind to SMAD-binding elements in target genes. Here, we
show that the thyroid hormone triiodothyronine (T3), through
binding to its nuclear receptors (TRs), is able to antagonize tran-
scriptional activation by TGF-β/SMAD. This antagonism involves
reduced phosphorylation of SMADs and a direct interaction of
the receptors with SMAD3 and SMAD4 that is independent of
T3-mediated transcriptional activity but requires residues in the
receptor DNA binding domain. T3 reduces occupancy of SMAD-
binding elements in response to TGF-β, reducing histone acetylation
and inhibiting transcription. In agreement with this transcriptional
cross-talk, T3 is able to antagonize fibrotic processes in vivo. Liver
fibrosis induced by carbon tetrachloride is attenuated by thyroid
hormone administration to mice, whereas aged TR knockout mice
spontaneously accumulate collagen. Furthermore, skin fibrosis in-
duced by bleomycin administration is also reduced by the thyroid
hormones. These findings define an important function of the
thyroid hormone receptors and suggest TR ligands could have
beneficial effects to block the progression of fibrotic diseases.
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TGF-β is a cytokine with pleiotropic effects in tissue homeostasisthat plays a key role in pathological processes such as cancer
and fibrosis (1). Fibrotic diseases, a leading cause of morbility and
mortality, are characterized by excessive deposition of extracel-
lular matrix, particularly collagen (2–4). TGF-β1, one of the TGF-β
isoforms, is the most potent profibrogenic factor. TGF-β signaling
promotes fibroblast differentiation into α-smooth muscle actin
(α-SMA) expressing myofibroblasts and stimulates collagen
deposition after a variety of injuries in tissues, including, among
others, the liver (5–8) and the skin (9). Furthermore, myofibroblast-
like cells respond to TGF-β by expressing increased amounts of this
factor, thus contributing to fibrosis development through autocrine
and paracrine loops of TGF-β‐stimulated collagen production (10).
TGF-β signals via type I and type II serine/threonine kinase
receptors. The main signaling pathway involves phosphorylation
of regulatory SMADs (mothers against decapentaplegic), such
as SMAD2 and SMAD3, which then associate with the cor-
egulatory SMAD4 and translocate to the nucleus (11, 12), where
in cooperation with other transcription factors (13), they stimu-
late transcription of target genes that contain SMAD binding
elements (SBEs). Recruitment of coactivators with histone acetyl
transferase activity leads to promoter acetylation and transcrip-
tional activation (14). Negative feedback is provided by SMAD-
induced expression of the inhibitory SMAD7, which leads to
polyubiquitylation and degradation of the TGF-β receptors (15).
SMAD factors have been shown to be essential mediators of the
fibrogenic actions of TGF-β (16–20).
The actions of the thyroid hormone triiodothyronine (T3) are
mediated by binding to nuclear receptors TRα and TRβ. TRα1
and TRβ1 are the two main thyroid hormone-binding isoforms
and regulate transcription either by direct binding to thyroid
hormone response elements (TREs) in target genes or by mod-
ulating the activity of other transcription factors and signaling
pathways (21, 22). TRβ mediates the majority of the actions of
T3 in the liver (23), playing an important role in regulating
metabolism (24, 25), regeneration (26), senescence (27), and
carcinogenesis (28). Recent findings suggest that nonalcoholic
fatty liver disease, which can progress to liver fibrosis, cirrhosis,
and hepatocellular carcinoma, is associated with impaired thy-
roid action in the liver (29–32). We have shown that expression
of TRβ1 in liver cancer cells represses TGF-β-mediated pro-
liferation and induction of metalloproteases (33), suggesting that
the receptor could antagonize the response to the growth factor
and, therefore, influence carcinogenesis. In this work, we dem-
onstrate that T3 binding to TRs antagonizes TGF-β/SMAD-
dependent transcription by a mechanism that involves a direct
interaction between the receptors and SMAD factors, reduced
SMAD phosphorylation, and decreased recruitment of SMADs
to the SBEs in target genes. The importance of this transcrip-
tional antagonism is demonstrated by the finding that the thyroid
hormones attenuate fibrotic processes in vivo in the mouse.
Results
T3 Antagonizes TGF-β/SMAD-Dependent Transcription. To analyze
whether thyroid hormone signaling could regulate TGF-β-mediated
transcription, we performed transient transfection assays in rat
pituitary GH4C1 cells, which are highly responsive to these
hormones, using the p3TP-lux reporter plasmid (34), bearing SBEs.
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dothyronine to the thyroid hormone receptors (TRs) antagonizes
TGF-β/SMAD (mothers against decapentaplegic)-dependent tran-
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coactivators retained most of the capacity of suppressing trans-
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fibrosis. These antagonistic actions on TGF-β/SMAD transcription
suggest that TR ligands might be used to block the progression of
fibrotic diseases. The natural hormone cannot be used clinically
because of severe adverse effects, but novel synthetic ligands with
fewer effects might be potentially developed and used.
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TGF-β markedly stimulated the activity of the reporter construct in
these cells, and a physiological T3 concentration strongly antago-
nized this response (Fig. 1A). The antagonism is not reciprocal, as
transactivation of a TRE-containing plasmid by T3 was not altered
in TGF-β-treated cells (Fig. 1B). To confirm that the antagonistic
effect of T3 was a result of inhibition of SMAD-dependent tran-
scription, and not to changes in TGF-β receptor expression or
activation, cells were transfected with expression vectors for
SMAD3 and SMAD4 and then incubated in the presence and
absence of T3. SMAD3 overexpression increased reporter activity
significantly, and this activity was further enhanced in the cells
transfected with the coregulatory SMAD4, which by itself lacks
transcriptional activity (12). T3 was able to markedly reduce
stimulation by these factors, showing that the hormone inhibits
TGF-β-dependent transactivation via regulation of SMAD activity
(Fig. 1C). This was further demonstrated by the finding that
TGF-β-dependent stimulation, as well as T3 antagonism, was
abolished after expression of the inhibitory SMAD7 (Fig. 1D).
Furthermore, a GAL-SMAD3 fusion plasmid was cotransfected
with a luciferase reporter plasmid containing binding motifs for
GAL4. GAL-SMAD3 consists of the DNA binding domain
(DBD) of GAL4 fused to SMAD3. In parallel with the observed
changes in transcriptional activity, incubation with TGF-β
strongly increased SMAD3-dependent gene expression, and this
response was reduced in T3-treated cells. In contrast, neither
TGF-β nor T3 affected the activity of a plasmid containing the
GAL4-DBD alone (SI Appendix, Fig. S1). Therefore, T3 ap-
pears to directly repress SMAD-dependent transcription.
The antagonistic effect of T3 was observed in cells transfected
with other SBE-bearing plasmids. Thus, SMADs stimulated the
activity of the Smad7 and p15 promoters, and T3 also antagonized
this activation (SI Appendix, Fig. S2A). To analyze whether the
antagonistic effect of T3 was observed in other cell types, the
p3TP–lux construct was transfected into human hepatocarcinoma
HepG2-TRβ cells that express ΤRβ1 in a stable manner. In-
cubation with TGF-β or transfection of SMAD3 and SMAD4 ac-
tivated the promoter, and T3 attenuated this activation, which was
again abolished by SMAD7, whereas T3-dependent transactivation
was not affected in TGF-β-treated cells, reproducing the results
obtained in GH4C1 cells (SI Appendix, Fig. S2B). Furthermore, T3
caused a strong reduction of SMAD-dependent transactivation in
murine neuroblastoma N2aβ cells expressing ΤRβ1, and a much
weaker but detectable inhibition in human HeLa cells that express
low endogenous levels of TRs (SI Appendix, Fig. S2C).
Both TRα and TRβ Can Mediate the Antagonistic Effect of T3 on TGF-
β/SMAD Signaling. To test whether or not TRα could also antag-
onize TGF-β/SMAD transcriptional activity, we used mink Mv1Lu
epithelial cells, a cell line widely used to study TGF-β signaling. In
these cells, T3 was unable to repress stimulation of the SBE-
bearing promoter by the TGF or SMADs. However, transfection
of either TRα or ΤRβ caused some ligand-independent SBE ac-
tivation, and T3 repressed very potently both basal activity and
transactivation by TGF-β or SMADs (SI Appendix, Fig. S3).
Therefore, both receptor isoforms appear to mediate hormone-
dependent repression of TGF-β/SMAD activity while inducing
activity in the absence of T3.
TR Domains Involved in Repression of TGF-β-Dependent Transcription
by T3. To identify the TR regions involved in this inhibition, we
cotransfected Mv1Lu cells with a SBE-bearing plasmid and ex-
pression vectors for the native receptors and different TRα and
ΤRβ mutants. Endogenous TR expression was not detected in
these cells, and the WT and mutant receptors were expressed at
comparable levels in the presence and absence of T3 (Fig. 2 C
and F). The mutations K288I and E457Q in ΤRβ and the equiv-
alent mutation E401Q in TRα are located in the ligand-binding
domain (LBD) and abolish the recruitment of coactivators and
T3-dependent transcription, although they still bind T3 (35).
However, these mutants maintain the ligand-independent activ-
ity and mediate significant T3-dependent repression of TGF-
β-dependent transactivation, although with less potency than the
WT receptors. In contrast, the TRα LBD alone was unable to
antagonize stimulation by TGF-β (Fig. 2A). The involvement of
the DBD in the antagonism, was proved using DBD mutants
(Fig. 2 B and E). Mutations C51G in TRα or C102G in ΤRβ
affect a conserved residue in the first zinc finger that participates
in the coordination of the zinc ion (36), and in the TRβ-GS120
mutant, two residues in the P-box sequence responsible for TRE
recognition were changed to those present in several steroid re-
ceptors, thus altering the specificity of DNA binding. In the ab-
sence of T3, expression of the DBD mutants did not increase
reporter activity in response to TGF-β and was unable to mediate
a significant ligand-dependent inhibition of TGF-β-mediated
transactivation. This suggests that residues in the DBD appear to
be required for T3-dependent antagonism of TGF-β-induced
transcription (Fig. 2 A and D). Other possible interpretation was
that the DBD mutants had enhanced inhibition of TGF-β signaling
that was not influenced by ligand. To sort out the possible expla-
nations for these functional results, we performed chromatin im-
munoprecipitation (ChIP) assays in GH4C1 cells to determine the
interaction of the wild-type and mutant receptors with a SBE re-
gion. Because these cells express predominantly TRβ, we found
that endogenous TRβ, but not TRα, was associated with the SBE
region, and that this association increased after overexpression of
the WT receptor and the LBD mutants. In contrast, binding of the
Fig. 1. T3 inhibits TGF-β-dependent transactivation. (A) Transient trans-
fection assays in GH4C1 cells with the reporter plasmid p3TP-lux bearing the
SBE-containing fragment of the PAI-1 (plasminogen activator inhibitor-1)
promoter. Luciferase activity was determined in cells incubated for 36 h with
5 nM T3 and 10 ng/mL TGF-β for the last 5 h. (B) Parallel experiments in cells
transfected with a reporter plasmid containing a consensus TRE. (C) Cells
were transfected with expression vectors for SMAD3 and/or SMAD4 or with
an empty vector (−), and luciferase activity was determined after 36 h in-
cubation in the absence and presence of T3. (D) Luciferase activity in cells
transfected with the empty vector or a SMAD7 vector and treated with T3
and/or TGF-β, as indicated. All data (mean ± SD; n = 3) are expressed as fold
induction over the values obtained in the untreated cells and are repre-
sentative of three independent experiments. Significance of ANOVA post-
test (Bonferroni) between T3-treated and untreated cells is indicated.
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DBD mutants was not observed, suggesting that residues in the
DBD are important for TR tethering to the SBEs (Fig. 2G).
TRs Interact with SMADs. To explore the mechanism underlying
T3-dependent inhibition of SMAD signaling, we analyzed the
possibility that TRs could interact with SMADs. GST pull-down
assays showed that SMAD3 and SMAD4 interacted similarly with
35S-labeled TRα and ΤRβ, and that this interaction was reduced by
T3 (Fig. 3A). Furthermore, the Mad Homology 1 (MH1) domain
of SMAD3 was sufficient to associate with the receptors (Fig. 3B).
Interaction of unliganded TR with SMAD3 and SMAD4 was
confirmed in extracts of Cos-1 cells transfected with Flag-ΤRβ and
incubated in the absence and presence of T3 (Fig. 3C) and in
coimmunoprecipitation experiments of HeLa cells transfected
with HA-SMAD4 and Flag-ΤRβ that showed association of the
receptor with SMAD4, which was also reversed in T3-treated cells
(Fig. 3D). Although both the transfected receptor and SMAD4
were more abundant in the nuclei, the interaction was detected
predominantly in the cytoplasmic fraction (Fig. 3E). Furthermore,
in GST pull-down assays, the LBD mutants TRα E401Q and ΤRβ
E457Q, which were able to mediate T3-dependent inhibition of
TGF-β transcriptional activity, showed a strong association with
SMAD3 and SMAD4, whereas the DBD mutants that showed
little inhibition of TGF-β signaling also showed a markedly re-
duced association with SMADs (Fig. 3 F and G). There was the
possibility that interaction of TRs with SMADs could disrupt the
formation of the complex between SMAD2/3 and the coregulatory
SMAD4. However, this interaction was not affected in T3-treated
cells (SI Appendix, Fig. S4).
T3 Reduces Stimulation of SMAD Phosphorylation in Response to TGF-β.
We next tested the possibility that T3 could alter SMAD phos-
phorylation. As shown in Fig. 4A, TGF-β induced a rapid and
strong increase of SMAD3 phosphorylation in GH4C1 cells that
was reduced in T3-treated cells. SMAD2/3 and SMAD4 levels
were not altered by the treatments, and quantification of the ratio
pSMAD/total SMAD confirmed that induction of SMAD3 phos-
phorylation by TGF-β was attenuated by the hormone. In addition,
immunofluorescence staining revealed that T3 caused a moderate
but detectable decrease of TGF-β-induced nuclear translocation of
SMAD2/3 (Fig. 4B). Reduced SMAD phosphorylation by T3 was
also observed in ΤRβ-expressing HepG2 cells, but not in the pa-
rental cells (SI Appendix, Fig. S5A), and a significant decrease of
nuclear pSMAD2 and SMAD2/3 accumulation was also observed
by Western blotting in these cells (SI Appendix, Fig. S5B).
T3 could reduce TGF-β stimulation of transcription by de-
creasing TR binding to SMADs, cytoplasmic SMAD3 phosphory-
lation, and nuclear transport or a combination of these events.
However, it was also possible that TR binding to SMAD3 could
regulate dephosphorylation in the nucleus, as dephosphorylation of
SMAD3 by the PPM1A phosphatase leads to its nuclear export
(37). To address these issues, we first compared the effect of T3 on
the TGF-β transcriptional response in Mv1Lu cells transfected with
GFP fusions of the native receptor or a TRβ mutant (2A mutant)
in the nuclear localization signal (38). We confirmed that the
transfected WT receptor was predominantly, but not exclusively,
nuclear, whereas the predominant nuclear localization was lost in
the 2A mutant (Fig. 5A). Interestingly, T3-dependent antagonism
of TGF-β transcriptional activity was lost in the mutant (Fig. 5B),
indicating that nuclear translocation of the receptor is required for
this effect, whereas some stimulation by the unliganded receptor
was still observed. In addition, analysis of total pSMAD3 levels by
Western blot showed that T3 reduced SMAD phosphorylation in
cells transfected with WT TRβ, but not in cells expressing an empty
vector or the TR2A mutant, and no changes in total levels of
SMAD2/3 and SMAD4 were observed (Fig. 5C). pSMAD levels
did not increase in cells transfected with the unliganded receptors,
but transfection efficiency was low (less than 15%), and therefore
the effect of TR and T3 could be underestimated. Thus, we next
analyzed the effect of WT and 2A receptors in SMAD3-transfected
Cos-1 cells, which have a better transfection efficiency. In Cos-1
cells, the main cytoplasmic distribution of the 2A receptor was also
observed (SI Appendix, Fig. S6A). The unoccupied receptors in-
creased pSMAD3 levels mainly in the cytoplasmic compartment,
although the WT receptor had a stronger effect. This confirmed
that, at least when overexpressed, TRs can induce a ligand-
independent effect (SI Appendix, Fig. S6A). In contrast, T3 re-
duced SMAD3 phosphorylation both in nuclei and cytoplasm of
cells expressing the native receptor, although this was not ob-
served with the 2A mutant (SI Appendix, Fig. S6B).
To analyze whether or not the hormone could regulate de-
phosphorylation in the nucleus, we next compared the effect of
T3 in Mv1Lu cells cotransfected with TRβ and WT SMAD3 or
with two mutants in the C-terminal SXS motif (S/D and S/E).
Fig. 2. TRα and TRβ domains involved in repression of TGF-β induced tran-
scription by T3. (A) Reporter assays in Mv1Lu cells transfected with a non-
coding vector or with vectors encodingWT and mutant TRα. Luciferase activity
was measured in cells incubated with T3 for 36 h and with TGF-β for the last
5 h. Results are expressed relative to the untreated cells transfected with an
empty vector. (B) Scheme of TRα showing the position of the mutations. AF-2,
ligand-dependent transcriptional activation function. (C) Western blot of TRα
in untreated and T3-treated cells transfected with the different mutants. The
arrow indicates the mobility of the TRα LBD. ERK2 was used as a loading
control. (D) Luciferase activity in cells transfected with the TRβ mutants in-
dicated and treated as in A. (E) Scheme of the mutations of TRβ used.
(F) Expression of TRβ mutants in transfected cells. All data are mean ± SD
(n = 3). Significance of ANOVA posttest (Bonferroni) of cells treated in the
absence and presence of T3 is indicated. (G) ChIP assays performed with con-
trol IgG and anti-TRα or anti-TRβ antibodies in GH4C1 cells transfected with an
empty plasmid (−) or with expression vectors for the indicated receptors.
Precipitated DNA was examined by quantitative RT-PCR with primers specific
for the SBE-containing region (−1,300/−1,042) of the Id1 promoter.
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These mutations should generate a constitutively active factor,
as they mimic phosphorylation and cannot be targeted by the
phosphatase. Both the native and mutant SMADs were expressed
at similar levels, but as expected, pSMAD3 was only detected in
cells transfected with WT SMAD (Fig. 5D). The S/D and S/E
mutants indeed acted constitutively, as they strongly increased
SBE-dependent transcription in the absence of phosphorylation.
In addition, TGF-β further increased transcriptional activation in
cells transfected with WT SMAD, although this factor had little if
any effect in cells transfected with the mutant SMADs. Interest-
ingly, T3 was still able to strongly reduce transcriptional activity of
both mutants, indicating that SMAD3 dephosphorylation by
PPM1A or other phosphatase/s does not play a major role in the
hormonal effect (Fig. 5E).
T3 Inhibits Recruitment of SMADs to TGF-β Target Gene Promoters.
Next, we confirmed that T3 repressed endogenous expression of
TGF-β target genes in GH4C1 cells. Transcripts for three well-
known TGF-β responsive genes, Smad7, Id1, and p15, were in-
duced by TGF-β, and this response was blunted in cells cotreated
with T3 (Fig. 6A). We then analyzed the possibility that T3 could
inhibit recruitment of SMADs to the promoters. ChIP assays with
the SBE-containing promoter regions (39–41) demonstrated that
the recruitment of SMAD2/3 and SMAD4 to these regions was
enhanced by TGF-β and that this interaction was significantly
attenuated in the presence of T3 (Fig. 6B). TRβ was present in the
TGF-β-target promoters in control and TGF-β-treated cells and
was released by the hormone. Because recruitment of histone
acetyltransferases plays a crucial role in TGF-β/SMAD transcrip-
tional responses (42), we also examined histone H4 acetylation in
the TGF-β target promoters in cells treated with T3, TGF-β, or
both. As expected, TGF-β increased the abundance of acetylated
histone H4 at the promoters, and this induction was also reversed
by T3 (Fig. 6B).
Thyroid Hormone Administration Alleviates Fibrotic Responses in
Vivo. In the light of the finding that T3 can antagonize TGF-
β/SMAD-dependent transcription, we hypothesized that thyroid
hormone treatment should also lead to a reduced susceptibility
of mice to developing fibrosis. We thus treated mice with T3 and
T4 in the drinking water before administration of carbon tetra-
chloride (CCl4), a widely used hepatotoxic agent (Fig. 7A). Oral
thyroid hormone treatment strongly increased circulating T3
levels. Because T3 treatment depletes pituitary TSH and blocks
endogenous thyroid secretion (43), mice were also given T4 to
maintain near-normal circulating levels of this hormone, although
Fig. 3. Interaction of TRs with SMADs. (A) Quantifications of pull-down assays with GST-SMAD-3 (G-S3) and GST-SMAD4 (G-S4) and in vitro translated TRα or
TRβ in the presence and absence of T3. Data are expressed as percentage of the inputs and are mean ± SD from three independent assays. Significant
differences in the absence and presence of T3 are indicated. (B) GST pull-downs of TRα and TRβ with SMAD3 or its N-terminal MH1 fragment. Data were
quantitated from two independent assays. (C) GST or GST-SMADs were incubated with 700 μg whole extracts of Cos-1 cells transfected with a Flag-tagged
TRβ and treated in the presence and absence of 50 nM T3 for 1 h. The bound receptor was analyzed by Western blot. The input represents 10% of the
proteins used in the binding assay. (D) HeLa cells were transfected with HA-SMAD4 and Flag-tagged TRβ, and 36 h later, they were treated with 50 nM T3 for
1 h. Immunoprecipitates (700 μg) with 3 μg anti-Flag antiserum or with a control serum (IgG) were subjected to Western analysis, together with 10% of the
cell extract (input) with SMAD4 or TRβ antibodies. (E) Cells were transfected with HA-SMAD4 and Flag-tagged TRβ, treated with T3, and cytoplasmic and
nuclear fractions were prepared and immunoprecipitations were performed as in D. (F) Quantification of in vitro GST pull-down assays of SMAD3 and SMAD4
with the indicated TRα and TRβ point mutants in the LBD and the DBD. Assays were performed in the presence and absence of T3 (G) Comparison of in-
teraction of the wild-type receptor with the indicated DBD mutants in GST pull-down assays. Results of F and G represent the mean values obtained in two
independent assays.
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they were still below the normal range. The increased circulating
levels of the active hormone T3, as well as the increased hepatic
Dio1 gene expression, an accurate functional marker of thyroid
hormone status, shows that the oral treatment induced functional
hyperthyroidism in the mice (SI Appendix, Fig. S7A). As shown in
Fig. 7B, acute treatment (48 h) with CCl4 caused significant he-
patocyte necrosis with nuclei loss in cells surrounding cen-
trilobular veins in normal mice, whereas this was not observed in
hyperthyroid mice. Decreased liver damage in thyroid hormone-
treated mice was confirmed by the markedly reduced induction of
serum aspartate aminotransferase (AST) activity by CCl4 (Fig.
7C). After acute liver injury, TGF-β enhances SMAD2/3 phos-
phorylation, which is involved in extracellular matrix deposition
and the development of liver fibrosis after chronic damage (44).
Thyroid hormone treatment decreased pSMAD2 and pSMAD3
levels both before and after CCl4 injection, and quantification of
the pSMAD/SMAD2,3 ratio confirmed the reduced SMAD2 and
SMAD3 activation in hyperthyroid livers (Fig. 7D). In addition,
the induction of Tgfβ1 and Egr-1 mRNA that occurs after acute
CCl4-induced liver injury in the normal mice (45) was abrogated
in thyroid hormone-treated mice (SI Appendix, Fig. S7B), showing
an early reduction of the response to CCl4 in these animals
compared with their control littermates. Suppression of the initial
liver response suggested that the thyroid hormones could prevent
subsequent development of liver fibrosis at later stages. Indeed,
hyperthyroid mice developed less severe liver fibrosis than control
mice after chronic exposure to CCl4 (three times per week for
30 d) (Fig. 8A). This difference was evidenced by significantly de-
creased Picrosirius red-positive area in histology (Fig. 8B), a lower
Ishak fibrotic score (Fig. 8C), reduced immunostaining of collagen
1 (Fig. 8D), and diminished AST activity (Fig. 8E). In accordance
with the reduced fibrosis, induction of α-SMA, the most reliable
myofibroblast marker, was significantly reduced in CCl4-treated
hyperthyroid mice (Fig. 8F). This finding was confirmed by
quantitative RT-PCR analysis that showed that hepatic α-Sma
mRNA levels were also lower in the hyperthyroid mice. Further-
more, thyroid hormone administration down-regulated hepatic
expression of the key fibrotic marker genes Col1a1 and Col1a2 in
response to CCl4, whereas at this time, it did not significantly
decrease Tgfβ1 mRNA levels (Fig. 8G).
Fig. 4. Effect of T3 on SMAD phosphorylation and translocation. (A) Western
blot analysis of GH4C1 cell extracts with phospho-SMAD3 (pSMAD3) and total
SMAD2/3 and SMAD4 antibodies after treatment with T3 for 36 h and with
TGF-β for the indicated periods. (Right) Quantification of the pSMAD3/
SMAD2,3 ratio from two independent experiments. Data are expressed as
fold-induction over the values obtained at time 0 in the untreated cells. (B) The
cells were incubated with T3 for 36 h and/or TGF-β during 60 min, fixed, and
analyzed by indirect immunofluorescence with SMAD2/3 antibody. Represen-
tative images of SMAD2/3, DAPI staining of nuclei, and merge images are
shown. (Right) Detail of the indicated areas. (Scale bar, 50 μm.)
Fig. 5. Nuclear translocation is required for T3 antagonism. (A) Representative
confocal images inMv1Lu cells transfected withWT TRβ fused to GFP and the 2A
mutant in the nuclear localization signal. (Scale bar, 10 μM.) (B) Cells were
transfected with an empty vector or with vectors encoding WT and 2A TRβ.
Luciferase activity was measured in cells incubated with T3 for 36 h and with
TGF-β for the last 5 h. (C) Western blot analysis of pSMAD3, total SMAD2/3, total
SMAD4, and ERK in cells transfected with the WT and mutant receptors and
treated with T3 for 36 h in the presence and absence of TGF-β for the last 30 min.
(D) Western blot analysis of pSMAD3 and SMAD2/3 in Mv1Lu cells transfected
with expression vectors for WT SMAD3 or with SMAD3 mutants in the SXS motif
(S/E and S/D). (E) Luciferase assays in Mv1Lu cells cotransfected with TRβ and WT
and mutant SMADs. After transfection, cells were incubated in the presence and
absence of T3 for 24 h and/or with TGF-β for the last 5 h. Luciferase results
(mean ± SD) in the different panels are expressed relative to the values obtained
in untreated cells transfected with empty vectors. Statistically significant differ-
ences between cells treated with and without T3 are indicated.
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The finding that thyroid hormone administration prevents liver
fibrosis led us to examine whether lack of thyroid hormone sig-
naling could promote fibrogenesis. For this purpose, we compared
livers of 18-mo-old wild-type mice and mice lacking both TRα1 and
TRβ, the main thyroid hormone binding isoforms. Indeed, all TR
KO mice exhibited spontaneously increased collagen deposition
assessed by Picrosirius staining, whereas no fibers were essentially
found in the livers of wild-type mice (Fig. 9 A and B). Collagen
fibers were present in the perisinusoidal Disse space, a pattern
characteristic of the initial stages of hepatic cirrhosis in human liver
pathologies. Histological findings were confirmed by the increased
hepatic expression of the profibrotic genes Tgfβ1 and Col1a1 in
TR-deficient mice (Fig. 9C). In addition, pSMAD3/SMAD2,3 ratio
was increased in the livers of double TR KO mice (Fig. 9D),
reinforcing the idea that regulation of SMAD activity by thyroid
hormone signaling could play a role in the fibrotic phenotype found
in TR KO mice.
We also tested the effect of thyroid hormone administration on
fibrosis, using a mice model of cutaneous scleroderma (Fig. 10A)
induced by repeated local injections of bleomycin in the dorsal skin
(46), in which SMAD-dependent signaling plays a crucial role (9,
17, 19). Thyroid hormone treatment caused the expected increase
of circulating T3, reduction of T4, and induction of hepatic Dio1
mRNA levels (SI Appendix, Fig. S8). In the bleomycin-injected
areas of euthyroid mice, we observed a significant increase of der-
mal thickness that was much less evident in thyroid hormone-
treated mice. In the control mice, these areas showed a high
accumulation of collagen fiber bundles in the dermis that extends
to the hypodermis, destroying the adipose tissue (Fig. 10B).
Quantification of the images indicated a significant increase of
the dermal connective tissue concomitant with an important re-
duction of the area of the hypodermis in euthyroid mice, which
was not observed in the hyperthyroid mice (Fig. 10C). Further-
more, the polarization of Picrosirius red staining showed a high
packaging of collagen fibers in the dermis of bleomycin-treated
controls. This polarized pattern is characteristic of increased
collagen presence in fibrotic areas. The collagen fibers were very
thick and compact in these animals, whereas samples from hy-
perthyroid mice treated with bleomycin showed a decrease of
thickness of bundle collagen fibers and extracellular matrix as-
sociated with low collagenization of the hypodermis (Fig. 10D).
Reduced skin fibrosis in bleomycin-treated hyperthyroid mice
was associated with reduced induction of α-SMA expression (Fig.
10E), with decreased pSMAD3 levels (Fig. 10F), and with a
significantly weaker induction of profibrotic genes (Fig. 10G).
Fig. 6. T3 represses stimulation of endogenous TGF-β target genes and in-
hibits in vivo occupancy of the promoters by SMADs. (A) Level of transcripts for
the Smad7 and p15 genes were determined by quantitative PCR in GH4C1 cells
treated with T3 for 36 h and TGF-β for the last 24 h. The early induction of Id1
mRNA was analyzed after 1 h treatment with TGF-β. Data are mean ± SD.
Significance of Bonferroni post hoc test (n = 3) is indicated. (B) ChIP assays
were performed with the indicated fragments of the TGF-β target promoters
that contain SBEs. Location of the primers used is shown with arrows, and the
SBEs are depicted as black boxes. Cells were treated for 1 h with T3 and/or
TGF-β and analyzed by ChIP with noninmmune IgGs, SMAD2/3, SMAD4, TRβ,
and acetylated histone H4 antibodies. One representative experiment of two is
shown. The input for each assay is also shown.
Fig. 7. Administration of thyroid hormones attenuates the acute hepatic re-
sponse to CCl4 treatment in mice. (A) Scheme of the treatments (vehicle, n = 4;
CCl4, n= 6). (B) RepresentativeMasson’s trichrome staining of livers of the different
experimental groups after acute CCl4 treatment, showing extensive damage with
nuclei loss only in euthyroid animals. (Scale bar, 50 μm.) (C) AST activity in serum.
Data are mean ± SEM. Significance of ANOVA posttest (Bonferroni) between eu-
thyroid and hyperthyroid CCl4-treated mice is indicated. (D) Western blot of
pSMAD2, pSMAD3, SMAD2/3, and SMAD4 in the livers after acute CCl4 treatment.
ERK2 was used as a loading control. (Right) pSMAD2/SMAD2,3 and pSMAD3/
SMAD2,3 ratios (mean ± SEM) were quantitated and are shown.
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Therefore, the thyroid hormones alleviate fibrotic responses in
vivo in two different models of TGF-β-dependent fibrosis.
Because fibroblast-like cells are the primary effectors for fibrosis
development, we examined the possibility that T3 could directly
inhibit TGF-β responses in primary cultures of fibroblasts. α-Sma
transcripts were strongly stimulated by TGF-β, and this response
was significantly attenuated in T3-treated cells (SI Appendix, Fig.
S9A). Furthermore, T3 also reduced induction of Tgfβ1 and Col1a1
by TGF-β, suggesting that the hormone could directly regulate
myofibroblast activation. As expected, this correlated with a re-
duced response to TGF-β and SMAD in transactivation assays and
a reduced induction of SMAD2 phosphorylation in the presence of
T3 (SI Appendix, Fig. S9 B and C).
Discussion
In this article, we show that the thyroid hormone-bound TRs
can attenuate TGF-β-mediated responses. Transcriptional ac-
tivity of TGF-β is mainly mediated by SMAD transcription
factors and in TR-expressing cells, T3 was able to repress acti-
vation of TGF-β target promoters containing binding sites for
these transcription factors. This antagonism occurred irrespective
of the promoter and in rat, mouse, mink, and human cells.
Therefore, the ability of T3 to repress SMAD transcriptional
activity is likely conserved across mammalian species. One of the
genes repressed by T3 was SMAD7, which acts as an attenuator
of SMAD-dependent transcription. Because of negative feed-
back, inhibition of SMAD7 expression could counteract the T3
suppressing effect of TGF-β signaling. However, both trans-
activation experiments and measure of TGF-β-stimulated tran-
scripts show that the inhibitory effect of T3 is predominant,
despite lower SMAD7 induction.
Transcriptional antagonism between nuclear receptors and
other transcription factors can involve direct protein-to-protein
interactions. We observed that the receptors associate with
SMAD3 and SMAD4 and that the MH1 domain of SMAD3 that
contains a DNA binding motif is involved in the interaction.
However, this association was significantly inhibited by T3 both
in vitro and in T3-treated cells. Therefore, a mechanism by which
hormone binding could promote TR/SMAD interactions and
formation of transcriptionally inactive complexes can be dis-
missed. Rather, the unoccupied receptors might act by enhancing
the activity or stability of transcriptional complexes by interaction
with SMADs, other transcription factors, or coregulators, and
this would be reversed in the presence of T3. This is suggested by
the finding that in ChIP assays, unoccupied TRs are tethered to
the SBE and are released by T3.
Mechanistically, we found that mutant receptors that are unable
to recruit classical coactivators and to mediate T3-dependent
Fig. 8. Administration of thyroid hormones attenuates liver fibrosis induced by CCl4 treatment in mice. (A) Scheme of the treatments (vehicle, n = 4; CCl4, n =
6). (B) Representative Picrosirius red staining of livers of euthyroid and hyperthyroid mice after chronic treatment with vehicle or CCl4. (Scale bar, 400 μm.)
Fibrosis was quantified from the stained area. (Right) Results (mean ± SEM) are shown. (C) Fibrosis grading with the Ishak score obtained with the same
samples. (D) Immunohistochemistry of Collagen1 expression. (Scale bar, 200 μm.) (E) Serum AST activity (mean ± SEM). (F) Western blot of α-SMA, pSMAD2,
and pSMAD3 in livers after chronic CCl4 treatment. ERK2 and SMAD4 were used as loading controls. (G) Relative mRNA levels of the fibrogenic genes α-Sma,
Tgfβ1, Col1a1, and Col1a2. Results (mean ± SEM) are expressed relative to the values obtained in control euthyroid mice treated with vehicle. Statistically
significant ANOVA posttest differences (Bonferroni) between CCl4-treated euthyroid and hyperthyroid groups are shown.
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transcriptional activation in transfection studies (35) still showed
significant repression of TGF-β/SMAD transcriptional activity, al-
though with less potency than the wild-type receptors. In addition,
analysis of DBD mutants revealed that residues in this domain are
required for repression of TGF-β-dependent transcription. DNA
binding is essential for many functions of TRβ in vivo, although
others can occur in its absence (47). The finding that mutations
C51G or C102G, which alter the structure of the DBD, do not show
repressive activity could be a consequence of its inability to bind
DNA. However, other explanations are possible, as these muta-
tions also display a strongly reduced interaction with SMADs and
cannot associate with the SBE-containing promoters. In addition,
the GS120 mutant (47) also shows reduced interaction with
SMADs, suggesting the DBD could be involved in mediating
antagonism independent of its capacity to bind a TRE. Therefore,
the inhibition of TFGβ transcriptional activity by the hormone
involves TR domains distinct from those responsible for classical
transcriptional activation that requires both binding to a TRE and
recruitment of coactivators. Furthermore, the parallelism of TR
mutants to mediate T3-dependent repression of SMAD tran-
scriptional activity, to associate with SMADs, and to be tethered
to the SBE suggests this interaction might be functionally impor-
tant for the antagonism observed.
Although the TR DBD appears to be required both for T3-
independent induction and T3-dependent inhibition of SMAD-
mediated transcriptional activity, a mutant receptor with a main
cytoplasmic localization still maintains some ligand-independent
effect, although T3-dependent antagonism appears to require a
more predominant nuclear receptor localization. Phosphorylation
of SMADs that increase nuclear uptake and DNA binding could
play a role in stimulation of transcription by the unliganded re-
ceptors, and indeed augmented pSMAD3 levels are found in the
cytoplasm of cells transfected with unoccupied receptors. However,
Fig. 9. Genetic deletion of TRs causes spontaneous liver fibrosis in aged
mice. (A) Picrosirius red staining in representative liver sections of WT mice
(n = 9) and KO mice (n = 5) lacking the thyroid hormone binding isoforms
TRα1 and TRβ. (Scale bar, 50 μm.) (B) Quantification (mean ± SEM) of the
Picrosirius red stained area. (C) Relative levels of Tgfβ1 and Col1a1 mRNA in
both groups. (D) Western blot of pSMAD3, total SMAD2/3, and ERK in livers
from WT and KO mice. (Right) pSMAD3/SMAD2,3 ratio (mean ± SEM)
obtained in four WT and six KO mice. Statistically significant unpaired two-
tail Student´s t test differences between WT and KO groups are shown.
Fig. 10. Thyroid hormone treatment alleviates skin fibrosis induced by
bleomycin administration. (A) Scheme of the experimental model (n = 6).
(B) Masson’s trichrome staining of skins. The red arrow shows the junction of
the dermis with the s.c. fat layer (hypodermis), and the black arrow marks
the muscle. (Scale bar, 200 μm.) (C) The percentage of the dermal connective
tissue and the area of the hypodermis were calculated from the stained
slides (mean ± SEM). ANOVA differences using the Bonferroni post hoc test
between vehicle and bleomycin-treated mice are indicated. (D) Represen-
tative Picrosirius red stained slides of the skin of the different experimental
groups observed under polarized light to detect collagen. (Scale bar,
200 μm.) (E) Western blot of α-SMA from skins of the different groups. ERK2
was used as a loading control. (F) Western blot of pSMAD3, SMAD2/3, and
ERK. (Right) Ratio pSMAD3/total SMAD in euthyroid and hyperthyroid ani-
mals. (G) Transcript levels of profibrotic genes (mean ± SEM) in the skin of
the different groups. Statistically significant ANOVA differences between
euthyroid and hyperthyroid mice treated with bleomycin are shown.
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increased transcriptional activity by unliganded TRs was obtained
under conditions of receptor overexpression, and therefore its
functional significance in vivo in cells expressing endogenous re-
ceptor levels is still unclear. The interaction of T3 with TR might
be reflected in an altered accessibility of SMAD complexes for
phosphorylation in response to TGF-β signaling. Indeed, we ob-
served that T3 partially blocked SMAD phosphorylation that is
required for nuclear translocation. In agreement with the idea that
TRs and SMADs shuttle between the nuclear and cytoplasmic
compartments (38, 48), we noticed the presence of a detectable
fraction of transfected native TRβ in the cytoplasm. Therefore,
SMADs and TRs could have the opportunity to form a complex in
this cellular compartment. Although we do not have a good ex-
planation for this observation, there was more TRβ/SMAD4 in-
teraction in the cytoplasmic fraction, even if both SMADs and the
receptor are more abundant in the nuclei. Furthermore, the A2
mutant receptor in the nuclear localization signal was ineffective in
mediating T3-dependent inhibition of SMAD phosphorylation and
TGF-β transcriptional activity, showing that TR nuclear trans-
location is required for these receptor actions. These results sug-
gested that T3-bound TRs could suppress TGF-β/SMAD signal
transduction by reducing the association of SMAD transcription
factors to TGF-β target genes. This was confirmed in ChIP assays
in which T3 significantly antagonized TGF-β-induced recruitment
of SMADs to the target promoters, thus inhibiting promoter
acetylation. This could be a result of reduced SMAD phosphory-
lation and nuclear translocation, and/or of a less-efficient binding
of SMADs to the SBEs in the presence of T3. There was also the
possibility that liganded TR may increase dephosphorylation of
pSMAD3 in the nucleus, leading to its nuclear export (37).
However, we ruled out the possibility that phosphatases could
play a major role in regulation of TGF-β/SMAD signaling by
the receptor.
The functional importance of the repression of TGF-β signaling
by hormone-bound TR was demonstrated in vivo, using mouse
models of fibrosis. During pathological fibrosis, tissue damage-
induced TGF-β signaling results in an excessive wound healing
response, characterized by synthesis of large amounts of extra-
cellular matrix promoted by the differentiation of fibroblasts, or
hepatic stellate cells in the case of the liver, into myofibroblasts
(49). Our results show that activation of TR signaling attenuates
the development of chemically induced liver and skin fibrosis,
reducing collagen deposition and α-SMA expression. Further-
more, fibrosis appears spontaneously in livers of mice in which
TRs have been genetically ablated, thus implicating these recep-
tors as physiological negative regulators of the fibrotic response in
vivo in this organ. Fibroblast activation by TGF-β1 induces pro-
fibrotic gene expression via SMAD binding to the SBEs, as well
as chromatin remodeling by histone acetylation. By decreasing
accessibility of SMADs to SBEs, liganded TRs could directly
antagonize myofibroblast activation and profibrotic gene ex-
pression, as observed here both in cultured cells and in vivo.
This TR/SMAD transcriptional cross-talk represents a pre-
viously unrecognized mechanism for regulating fibrotic pro-
cesses. However, we cannot exclude the possibility of multiple
suppressive effects of TR on fibrogenesis. For instance, in-
flammation appears to play an important role on the initial
stages of fibrosis, sensitizing cells for TGF-β/SMAD activation
(4, 7), and we have previously shown that TR deletion increases
inflammatory responses in the skin (50). Although the role of
TRs in the inflammatory reaction to CCl4 or bleomycin ad-
ministration remains to be explored, it is possible that a reduced
inflammation as a consequence of increased TR signaling could
also play a role in the observed antifibrotic effects of the thyroid
hormones in vivo.
Previous studies have reported that both a deficiency and an
excess of thyroid hormones could inhibit fibrosis. Thus, it has
been reported that hypothyroidism induced by antithyroidal
drugs can prevent pulmonary and cutaneous fibrosis induced
by hypochlorous acid (51) and to improve survival after acute
thioacetamide administration in the rat (52). However, hypo-
thyroidism also induces cardiac fibrosis in the rat (53, 54), thyroid
hormone administration ameliorates kidney fibrosis (55), and
thyroid disfunction and subclinical hypothyroidism have been
associated with primary biliary cirrhosis, primary sclerosing chol-
angitis, and nonalcoholic fatty liver disease in humans (29, 32).
These observations reveal the complex role of the thyroid hor-
mones on fibrosis that could depend on the type of insult or tissue
examined. In the case of the liver, and in agreement with our
results, a TRβ selective analog was effective at reducing hepatic
disease and carcinogenesis in rodents (28, 29, 32). Although the
natural hormone and TR agonists present adverse effects (21, 24),
novel thyromimetic drugs with fewer adverse effects might be
potentially developed and used to block the progression of fibrotic
diseases. Recently, it has been reported that other ligands of nu-
clear receptors can also repress fibrosis. In particular, vitamin D
receptor signaling prevents CCl4-induced liver fibrosis, inhibiting
SMAD3 occupancy and SMAD-dependent transcriptional activity
(56). Furthermore, vitamin D receptor agonists without hyper-
calcemic effects showed antifibrotic activity (57). This serves as a
proof of concept that development of nuclear receptor ligands
capable of disrupting TGF-β/SMAD activity could constitute a
novel pharmacological approach to treat human diseases.
Materials and Methods
Extended materials and methods are provided in SI Appendix. Animal studies
were approved by the Ethics Committee of the Consejo Superior de Inves-
tigaciones Científicas. Mice were made hyperthyroid by adding thyroxine and
T3 to the drinking water. Circulating thyroid hormones were measured by RIA
(43). Euthyroid and hyperthyroid animals were subjected to a liver fibrosis
protocol by i.p. administration of CCl4 and to a bleomycin model of skin fi-
brosis, as detailed in the SI Appendix. Double KO mice for TRα1 and TRβ have
been described (50). Experimental procedures for transfections, luciferase re-
porter assays, Western blot, GST pull-down assays, coimmunoprecipitation,
mRNA determination by real-time PCR, and chromatin immunoprecipitation
assays have been published previously and are described together with the
antibodies and primers used in SI Appendix. Histology, immunohistochemistry
and morphometric analysis were performed by standard procedures and are
described with more detail in SI Appendix. Significance of ANOVA posttest or
the Student t test among the experimental groups indicated in the figures is
shown as *P < 0.05, **P < 0.01, and ***P < 0.001.
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